About Ernexa Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ernexatx.com/
Frequently Asked Questions
What is the 52-week range for ERNA?
The 52-week high is $71.5 and the 52-week low is $2.84.
What is the P/E ratio for ERNA?
The P/E ratio data is currently unavailable.
What is the dividend yield for ERNA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -169.40%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7720.96%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.92.
Analyst Recommendation Trends
Wall Street analyst consensus for ERNA over the last few months:
Latest ERNA News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 56.7% to $0.16 during Friday's pre-market session. Stablecoin Development (AMEX:SDEV) stock rose 30.86% to $4.79. The company's market cap stands at
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1 Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors Access the Ernexa CEO Corner here CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing nov
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy Biodistribution study showed no significant ERNA-101 signal in tumor-free
Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards by
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October 6, 2026, at 1:30 PM Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101 in platinum-resistant ovarian cancer and its potential for broader expansion across ovarian cancer and other solid tumor indications Differentiated synthetic iMSC platform design
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology Positive ERNA-201 findings add to a growing body of preclinical evidence supporting the versatility of Ernexa's synthetic iMSC platform and its ability to deliver engineered therapeutic factors in disease Company is concentrating near-term resources on ERNA-101 while broadening
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Ratner Elena | +5,944 | - | - |
| 2026-08-31 | Cicala Peter | +5,083 | - | - |
| 2026-08-31 | Cicala Peter | +5,943 | - | - |
| 2026-08-31 | Luther Sanjeev | +118,848 | - | - |
| 2026-08-31 | Wexler William A. | +5,943 | - | - |
| 2026-08-31 | Polinsky David | +5,083 | - | - |
| 2026-08-31 | Bristol James Arthur | +5,083 | - | - |
| 2026-08-31 | Bristol James Arthur | +8,320 | - | - |
| 2026-02-10 | Cherington Charles | +4,000,000 | - | - |
| 2026-02-10 | Cherington Charles | +4,000,000 | $0.5 | $2,000,000 |